Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal.</li><li>Global revenue was $2.5 billion, flat on a reported basis and down 1% organically.</li><li>Adjusted net income declined 2% organically, with international revenue rising 6% and U.S. revenue falling 7%.</li></ul>

Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal.Global revenue was $2.5 billion, flat on a reported basis and down 1% organically.Adjusted net income declined 2% organically, with international revenue rising 6% and U.S. revenue falling 7%.

Zoetis Is Not Just A Companion Animal Story — Livestock Revenue Jumps 11%!

<ul><li>Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial relationship that began in August 2025.</li><li>Under that partnership, VitalRADS supplied remote radiology interpretations through the Zoetis Virtual Laboratory, giving clinics access to specialist reviews without requiring an on-site radiologist.</li><li>The proposed transaction, expected to close in the third quarter of 2026, would add a network of board-certified veterinary specialists covering more than 25 species, alongside VitalPACS cloud-image storage, an outpatient imaging center in Cypress, Texas, and mobile ultrasound operations in Houston and Seattle.</li></ul>

Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial relationship that began in August 2025.Under that partnership, VitalRADS supplied remote radiology interpretations through the Zoetis Virtual Laboratory, giving clinics access to specialist reviews without requiring an on-site radiologist.The proposed transaction, expected to close in the third quarter of 2026, would add a network of board-certified veterinary specialists covering more than 25 species, alongside VitalPACS cloud-image storage, an outpatient imaging center in Cypress, Texas, and mobile ultrasound operations in Houston and Seattle.

Zoetis Acquisition Of VitalRADS Signals A Bigger Diagnostics Push!

<ul><li>Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its key business segments and geographies.</li><li>On an organic operational basis, total company revenue was flat compared to the prior year, while adjusted net income increased by 1%.</li><li>The International segment demonstrated strong growth, with a 10% increase organically, whereas the U.S. segment faced an 8% decline.</li></ul>

Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its key business segments and geographies.On an organic operational basis, total company revenue was flat compared to the prior year, while adjusted net income increased by 1%.The International segment demonstrated strong growth, with a 10% increase organically, whereas the U.S. segment faced an 8% decline.

Zoetis’ 8% U.S. Decline: Can Livestock Growth Offset Pet-Care Pressure?

<ul><li>Zoetis Inc., a leading global animal health company, reported its financial results for the fourth quarter and full year of 2025.</li><li>The company experienced a 6% organic operational revenue growth for the full year, alongside a 7% increase in adjusted net income, aligning with previous expectations.</li><li>This growth was driven by contributions from both international markets, achieving an 8% growth, and the U.S. with a 4% growth.</li></ul>

Zoetis Inc., a leading global animal health company, reported its financial results for the fourth quarter and full year of 2025.The company experienced a 6% organic operational revenue growth for the full year, alongside a 7% increase in adjusted net income, aligning with previous expectations.This growth was driven by contributions from both international markets, achieving an 8% growth, and the U.S. with a 4% growth.

Zoetis: How Portfolio Diversification Is Strengthening Its Competitive Moat!

<ul><li>Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income on an organic operational basis.</li><li>The results were fueled by strong performances in both international and U.S. markets, with international revenue growing by 6% and U.S. revenue by 3% when excluding divestitures.</li><li>However, this growth was moderated compared to previous quarters due to various market dynamics and challenges.</li></ul>

Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income on an organic operational basis.The results were fueled by strong performances in both international and U.S. markets, with international revenue growing by 6% and U.S. revenue by 3% when excluding divestitures.However, this growth was moderated compared to previous quarters due to various market dynamics and challenges.

Zoetis Surges Forward as Librela Stabilizes—Signaling a Major Comeback in 2026!

United States

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets its products in North America, Europe, Africa, Asia, Australia, and Latin America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zoetis (ZTS UN)

Zoetis Is Not Just A Companion Animal Story — Livestock Revenue Jumps 11%!

Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal. Global...

Baptista Research

Zoetis Acquisition Of VitalRADS Signals A Bigger Diagnostics Push!

Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial...

Baptista Research

Zoetis’ 8% U.S. Decline: Can Livestock Growth Offset Pet-Care Pressure?

Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its...

Baptista Research

Zoetis: How Portfolio Diversification Is Strengthening Its Competitive Moat!

Zoetis Inc., a leading global animal health company, reported its financial results for the fourth quarter and full year of 2025. The company...

Baptista Research

Zoetis Surges Forward as Librela Stabilizes—Signaling a Major Comeback in 2026!

Zoetis recently reported its third quarter financial results for 2025, revealing a 4% growth in revenue and a 9% increase in adjusted net income...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)